نتایج جستجو برای: isoniazid

تعداد نتایج: 5604  

2009
Indra L. Bergval Anja R. J. Schuitema Paul R. Klatser Richard M. Anthony

OBJECTIVES The high prevalence of isoniazid-resistant Mycobacterium tuberculosis is often explained by a high mutation rate for this trait, although detailed information to support this theory is absent. We studied the development of isoniazid resistance in vitro, making use of a laboratory strain of M. tuberculosis. METHODS Spontaneous isoniazid-resistant mutants were characterized by molecu...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007
Nikos P Spyridis Panayotis G Spyridis Anna Gelesme Vana Sypsa Mina Valianatou Flora Metsou Dimitris Gourgiotis Maria N Tsolia

BACKGROUND A 9-month course of isoniazid monotherapy is currently recommended for the treatment of latent tuberculosis infection (LTBI) and has been shown to be effective in both children and adults. Reduced compliance with this regimen has forced physicians to explore shorter regimens. The aim of this study was to compare 3- and 4-month combination regimens of isoniazid plus rifampin with a 9-...

Journal: :American journal of respiratory and critical care medicine 2009
David P Holland Gillian D Sanders Carol D Hamilton Jason E Stout

RATIONALE Isoniazid given daily for 9 months is the standard treatment for latent tuberculosis infection (LTBI), but its effectiveness is limited by poor completion rates. Shorter course regimens and regimens using directly observed therapy result in improved adherence but have higher upfront costs. OBJECTIVES To evaluate the costs and cost-effectiveness of regimens for the treatment of LTBI....

2011
David P. Holland Gillian D. Sanders Carol D. Hamilton Jason E. Stout

RATIONALE Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability. OBJECTIVES To inform clinical trial design by estimating the potential costs and effectiveness of rifapentine-based regimens for treatment of latent tuberculosis infection (...

B. Nasr Esfahani G. Asghari P. Paydar

Background and objectives: Tuberculosis (TB) is the major public health problem in the world. Each year there are 2-3 million deaths worldwide caused by TB. The increasing incidence of Multi Drug Resistance tuberculosis (MDR-TB) worldwide highlights the urgent need to search for new anti-tuberculosis compounds. It has been reported that medicinal plant, Dracocephalum kotschyi, possesse...

Journal: :Antimicrobial agents and chemotherapy 2004
Chiu-Yeung Chan Carrie Au-Yeang Wing-Wai Yew Chi-Chiu Leung Augustine F B Cheng

Postantibiotic effects (PAEs) of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis ATCC 27294 were studied using a radiometric culture system. Rifapentine at 20 mg/liter gave the longest PAE (104 h) among the drugs used alone. The combinations of rifapentine plus isoniazid, rifapentine plus moxifloxacin, and isoniazid plus moxifloxacin gave PAEs of 136.5, 59.0, and 8.3...

2013
Paolo Ascenzi Andrea Coletta Yu Cao Viviana Trezza Loris Leboffe Gabriella Fanali Mauro Fasano Alessandra Pesce Chiara Ciaccio Stefano Marini Massimo Coletta

Isoniazid represents a first-line anti-tuberculosis medication in prevention and treatment. This prodrug is activated by a mycobacterial catalase-peroxidase enzyme called KatG in Mycobacterium tuberculosis), thereby inhibiting the synthesis of mycolic acid, required for the mycobacterial cell wall. Moreover, isoniazid activation by KatG produces some radical species (e.g., nitrogen monoxide), t...

Journal: :Antimicrobial agents and chemotherapy 2000
A S Piatek A Telenti M R Murray H El-Hajj W R Jacobs F R Kramer D Alland

Past genotypic studies of Mycobacterium tuberculosis may have incorrectly estimated the importance of specific drug resistance mutations due to a number of sampling biases including an overrepresentation of multidrug-resistant (MDR) isolates. An accurate assessment of resistance mutations is crucial for understanding basic resistance mechanisms and designing genotypic drug resistance assays. We...

Journal: :The New England journal of medicine 2011
Timothy R Sterling M Elsa Villarino Andrey S Borisov Nong Shang Fred Gordin Erin Bliven-Sizemore Judith Hackman Carol Dukes Hamilton Dick Menzies Amy Kerrigan Stephen E Weis Marc Weiner Diane Wing Marcus B Conde Lorna Bozeman C Robert Horsburgh Richard E Chaisson

BACKGROUND Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion. METHODS We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly ther...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید